by 
Throughout the COVID-19 pandemic, Galaxy Diagnostics’ research and development team has remained dedicated to advancing diagnostics for flea- and tick-borne diseases. In this new brochure, we discuss Lyme borreliosis and the advantages of our revolutionary Nanotrap® test that was launched last year.
Lyme borreliosis is a tick-borne disease that causes both acute and chronic symptoms affecting the heart, joints, central nervous system, and more. Although a clinical diagnosis can be made by a healthcare provider based on symptoms, it is often not that straightforward. Patients can present with atypical or non-specific symptoms that can be difficult to distinguish from other conditions that generate nonspecific symptoms, such as “long” COVID-19. They also may not remember being bitten by a tick, making it difficult to evaluate their exposure risks.
This makes laboratory testing an important tool for healthcare providers seeking more accurate diagnoses for their patients. However, there are challenges to testing as well. Results from serology testing, such as Western blot or ELISA, are difficult to interpret, especially for complex illnesses in which many confounding factors may be involved. Standard direct testing methods, like PCR, are often not sensitive enough for low-level Borrelia infections and can result in a high rate of false negatives.
Our goal at Galaxy Diagnostics is to raise awareness of flea- and tick-borne diseases and advocate for testing strategies that go beyond the limits of detection. The Nanotrap® Antigen Test is one way that we are going beyond to improve clinical care of Lyme disease patients.
Published data show the Nanotrap® Antigen Test is very effective for confirmation of early-stage Lyme disease in patients with EM rashes (24/24). Further, our validation data suggest it detects positive cases missed by two-tiered testing.
We encourage you to share this latest brochure with family, friends, and colleagues who may be interested in learning more about Lyme borreliosis and testing that Galaxy Diagnostics offers.
Galaxy Diagnostics. (2019, May 22). How vector-borne diseases impact heart health. https://www.galaxydx.com/bartonella-lyme-impact-heart-health/
Walker, J. (2020, July 8). Lyme disease and COVID-19 can share similar symptoms what happens when coronavirus and Lyme disease intersect? https://today.uconn.edu/2020/07/lyme-disease-covid-19-can-share-similar-symptoms/#
Galaxy Diagnostics. (2019, July 31). The basics of serology. https://www.galaxydx.com/the-basics-of-serology/
Magni, R. et al. (2015). Application of Nanotrap technology for high sensitivity measurement of urinary outer surface protein A carboxyl-terminus domain in early stage Lyme borreliosis. Journal of Translational Medicine, 13, 346. 10.1186/s12967-015-0701-z https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4634744/